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Summary
Objectives—As part of an investigation of connecting health professionals and the lay public to
both disease and genomic information, we assessed the availability and nature of the data from the
Human Genome Project relating to human genetic diseases.
Methods—We focused on a set of single gene diseases selected from main topics in MEDLINEplus,
the NLM’s principal resource focused on consumers. We used publicly available websites to
investigate specific questions about the genes and gene products associated with the diseases. We
also investigated questions of knowledge and data representation for the information resources and
navigational issues.
Results—Many online resources are available but they are complex and technical. The major
challenges encountered when navigating from phenotype to genotype were (1) complexity of the
data, (2) dynamic nature of the data, (3) diversity of foci and number of information resources, and
(4) lack of use of standard data and knowledge representation methods.
Conclusions—Three major informatics issues arise from the navigational challenges. First, the
official gene names are insufficient for navigation of these web resources. Second, navigational
inconsistencies arise from difficulties in determining the number and function of alternate forms of
the gene or gene product and maintaining currency with this information. Third, synonymy and
polysemy cause much confusion. These are severe obstacles to computational navigation from
phenotype to genotype, especially for individuals who are novices in the underlying science. Tools
and standards to facilitate this navigation are sorely needed.
Keywords
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Introduction
The human genome sequence contains the genetic code that forms the basis of each human
being. The human DNA sequence, determined by the massive Human Genome Project (HGP)
that spans multiple laboratories, countries and continents, was completed in draft form in the
spring of 2001 [1]. The subsequent activities have concentrated on progressing from draft form
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to completed form, switching to a focus on the determination of what are the functions of the
genes, and what variations exist in the genome. The information arising from the HGP promises
to alter our perceptions of disease and health and to change the way medicine is practiced. The
nature of our genes and how they give rise to various illnesses (both the common diseases of
middle/advanced age and the rarer single gene disorders) are being explored in depth with the
potential of improved health and longevity for the public.
The publicity associated with the HGP has led many people to ask questions about the health
implications and specifically, “What data are coming from the Human Genome Project that
relate to my disease and my risks for disease?” An exploration of the databases that hold the
information about connections between specific genes and diseases reveals 1400 human genes
that have been proven to cause at least one disease and where the DNA sequence and molecular
function are determined.1 This extensive information is available over publicly accessible
internet sites, but not easily accessible to the public because of its technical nature.
This project was undertaken to assess what data from the HGP are available on common
inherited diseases and how accessible the data are to the lay public. The work focused on the
major information resources containing consumer health information, genome and proteome
knowledge and the methods to navigate among them. This paper will focus on informatics
issues that arise when navigating the information systems with the HGP data. The project
provides the foundation for creating an integrated information system to connect the public to
the health implications of the HGP data.
Background
Over 300 information resources are publicly available over the internet and have data
associated with various aspects of genes, gene function, and diseases across multiple species
[2]. Table 1 lists some of the major information resources containing data that relate directly
to human genetic diseases or to data from the Human Genome Project that relate directly to
human genes that cause disease. The basic data of the HGP (and all other species) resides in
synchronized sequence databases held by the National Library of Medicine’s (NLM) GenBank
[3], the DNA Data Bank of Japan (DDBJ) [4] and the European Molecular Biology
Laboratory’s (EMBL) Nucleotide Sequence Database [5]. The data pertaining to the gene
products arising from these sequences are contained in databases held by the same three groups
in the LocusLink [6], SWISS-PROT/TrEMBL [7], and KEGG [8] systems, but also in various
other public resources. The major resource for human genetic diseases is the Online Mendelian
Inheritance in Man (OMIM) [9] catalog of human genes and human genetic diseases, closely
linked to other NLM resources. The scientific literature references for all of this work are held
in MEDLINE [6] by the NLM. Most of the other gene resources listed in Table 1 are derived
from these basic sources and add value to them in numerous ways.
Some consumer-focused information resources have information on genetic diseases, but the
consumer resources are not usually closely interlinked with the molecular biology
databases.The NLM has two such resources: MEDLINEplus [10] with over 100 genetic
diseases in its main topics and subtopics, and ClinicalTrials.gov [11] with information on
clinical trials for many genetic diseases. The GeneTests [12] system of the University of
Washington is focused on health professionals rather than the public. It lists commercially
available laboratory tests for the genetic diseases; the related Gene Reviews presents clinical
summaries done by genetics experts.
1Results from a search on 12-19-2002 of Locus-Link with the query has_seq AND disease_ known AND organism = human.
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An analysis in June 2002 of MEDLINE-plus, the NLM’s principal resource focused on
consumers, revealed that several specific inherited diseases were main topics or subtopics in
MEDLINEplus and also fulfilled four other criteria: 1) entries in OMIM for a specific disease,
2) entries in LocusLink for specific gene products for the OMIM disease, 3) disease summary
in GeneReviews; and 4) at least three commercial laboratories doing DNA tests as listed in
GeneTests. Thirteen of these diseases were examined in detail to investigate the potential
navigation from phenotype (disease) to genotype and the current systems that contained the




• Duchenne muscular dystrophy
• Gaucher disease
• Huntington disease





• polycystic kidney disease
• tuberous sclerosis.
The selection as a topic or subtopic in MEDLINEplus guarantees a range of materials on patient
education2, family support3, glossaries of genetics concepts4 and explanations of genetic
testing5.
The specific questions of this study related to where genetic data that would potentially be of
interest to patients and their families as well as health care professionals could be found. The
questions arose from experience with genetic counseling sessions where these were the
questions often asked by patients or considered important by genetic counselors before giving
an informed prognosis and risk estimates to the patients.
• What gene(s) causes the disease?
• On which chromosomes are the genes located?
• What are the normal functions of the gene product(s)
• What mutations have been found in the genes?
• What are the functions of the mutated gene product(s)?
• Which laboratories are performing DNA tests for the mutations?
2JAMA patient page: www.ama-assn.org/public/journals/patient/archive/pat1114.htm
3Genetic Alliance: www.geneticalliance.org/
4Genetics Education Center: www.kumc.edu/gec/
5Nemours Foundation: http://kidshealth.org/parent/system/medical/genetics.html
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• Are there gene therapies or clinical trials for the disease?
• Do the genes cause any other diseases besides the target disease?
• What names are used to refer to the genes and the diseases in these resources?
The study considered where the information resided to answer these questions and the
navigation issues encountered. We also investigated whether the genes, gene products and
diseases were included in the Unified Medical Language System® version 2002AA
(UMLS®)6 in order to determine if these specific concepts were included in the vocabularies
covered by that system. We considered questions of knowledge and data representation for the
information resources and navigational questions among systems. The systems where these
questions were investigated were the publicly available resources listed in Table 1 that also
lists the URLs for all of the systems described in this paper. The search strategies were executed
and the data evaluated by the first author who is trained in both medical genetics and
informatics.
Results
The results will be presented in two examples, one for the disease achondroplasia and one for
the disease Marfan syndrome. Table 2 presents the answers to the nine questions for the disease
achondroplasia. This example serves to demonstrate the type and complexity of the data. The
system navigation from a consumer system (MED-LINEplus) to the bioinformatics resources
for the genotype information is given by the example of the disease Marfan syndrome. Figure
1 illustrates the path through the information resources used to answer the questions about
Marfan syndrome; the traversal was from the consumer health resources through disease-
related resources and then to the bioinformatics resources. Table 3 shows the information
resources that in general hold answers to the questions of this study.
All of the data sought for the set of thirteen diseases was found in the systems navigated,
although the full description of normal gene function was not always satisfactory without
reading the primary literature. It was easier to navigate completely online from phenotype to
genotype with some of the diseases investigated than with others. An example comes from the
Marfan Syndrome and is shown in Figure 1. Four of the thirteen diseases can be traversed in
an analogous manner (Gaucher disease, Huntington disease, Marfan Syndrome, myotonic
dystrophy (for one of the two causative genes)). Genes and Disease serves as the only linking
system between the consumer-health oriented MEDLINE-plus system and the knowledge
bases of molecular biology. Without a linking system, the phenotype-genotype connections
are much more difficult when starting from MEDLINEplus and rely entirely on the prior
knowledge of the navigator. Clinical trial information would only come through a link from
the MEDLINEplus page to ClinicalTrials.gov since none of the other systems link their users
directly to the clinical trials for the diseases in question.
For these thirteen target diseases, there were 31 genes, 189 gene names, 59 gene products
(including isoforms), 56 associated diseases, and 240 disease names. The list of synonyms for
the gene and gene product names is undoubtedly incomplete because there is no general
agreement on what names to use and because there is no single source to collect all of them.
All of the thirteen target diseases were represented in the UMLS and the Medical Subject
Headings (MeSH)7 used to index the literature; in some cases the specific disease name or
subtype name was not found in MeSH as a main heading but rather was an entry term for a
more general disease category (e.g., MeSH includes muscular dystrophies as the official MeSH
6Unified Medical Language System: http://umlsinfo.nlm.nih.gov/
7Medical Subject Headings (MeSH): www.nlm.nih.gov/mesh/
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Heading but includes the multiple types of muscular dystrophy as entry terms). The full list of
diseases caused by the genes was not always found in the UMLS (including MeSH). 28 of the
31 genes were found in both UMLS and MeSH; two gene products were found in a general
category but not the specific gene; one gene (FKRP) was not found in 2002 UMLS and is still
not in the 2003AA UMLS. In general, the phenotype to genotype knowledge is most sketchy
as it relates to a description of normal function of the genes.
Four major challenges were encountered when navigating from phenotype to genotype:
1. Complexity of data: The sheer complexity and volume of the data emanating from
the HGP is daunting even to the scientific community. The gene names and gene
product names are especially complex. The number of synonyms and the non-intuitive
nature of the synonyms for various diseases, genes, and gene symbols make it difficult
to find comprehensive information. The nomenclature committee of the Human
Genome Organization (HUGO) decides upon an “official” gene name and gene
symbol and keeps an online database with the official name and symbol. However,
the official gene names are the result of scientific compromise and debate, and are
frequently unwieldy and difficult to remember or use computationally, inviting the
use of more synonyms. For example, the official name for the gene that when mutated
causes Duchenne and Becker Muscular Dystrophy and X-linked cardiomyopathy is
dystrophin (muscular dystrophy, Duchenne and Becker type). Most people abbreviate
this to dystrophin, even though this makes the name identical to the name for the gene
product in the rat (Dystrophin) (note upper case D) and the fruit fly (dystrophin) (note
lower case d) and similar to that of the mouse (dystrophin, muscular dystrophy).
Furthermore, many knowledge bases throughout the world do not uniformly use the
official gene names and gene symbols. For example, for the gene that when mutated
causes myotonic dystrophy type 1, the official gene product name is dystrophia
myotonica-protein kinase and the official symbol is DMPK. But SWISS-PROT uses
the entry name DMK_HUMAN and the protein name myotonin-protein kinase.
Neither the SWISS-PROT entry name or protein name is included in the synonym
list of Locus-Link or the HGNC database. However, the only entry terms into the
Gene Ontology database are the SWISS-PROT ID or entry names.
The official gene names often include metadata that link to one or more diseases,
although not necessarily the complete list of diseases. The fibroblast growth factor
receptor 3 (achondroplasia, thanatophoric dwarfism) gene gives metadata about two
of the eleven disorders caused by mutations in the gene. Besides disease name, other
metadata are often included in the gene names or symbols, including the species (e.g.,
FBN1_HUMAN), the disease inheritance pattern (e.g., polycystic kidney disease 1
(autosomal dominant)), and the biochemical pathway (e.g., polycystin precursor).
While it is not exceptional in biomedical terminology to have metadata as part of the
terms, the extent to which this occurs in the human genes names is exceptional.
2. Dynamic nature of the data: The existing scientific and clinical systems are in a
constant state of flux because of the rapidity of developments coming from a global
research effort. The situation is unlikely to settle down within the foreseeable future.
From the time a journal article appears with a new disease-gene connection, it takes
almost six months for the knowledge to cascade through all of the interconnected
bioinformatics systems. The nature and number of gene products is still scientifically
labile. More examples of genes with multiple gene products (isoforms) arise daily,
some of which are active in specific tissues or at a specific developmental stage. For
example, the human dystrophin gene produces eighteen known isoforms from the use
of alternate promoters or alternate exons. Knowledge about these situations is still
emerging.
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3. Diverse foci and number of data/knowledge base systems: Table 1 only lists a
handful of the information resources available with data from the HGP. With over
300 resources, it is a daunting task to gather all of the information and navigate the
systems. Further, most of the existing systems with information related to the data
from the HGP are focused on the scientific or subspecialty medicine communities and
presuppose a working knowledge of the science behind the databases and the tools.
Most systems focused on consumer access to health information, such as
MEDLINEplus, do not generally link to the genomics knowledge bases because of
the lack of an obvious way to connect the two worlds. Furthermore, the scientific and
clinical databases are difficult for the general public to comprehend, and the consumer
systems do not link to them largely for this reason.
4. Data and knowledge representation: The lack of standard methods for representing
the data makes it a challenge to navigate manually or to manipulate those data
computationally. The data fields often include information that does not strictly
adhere to the definition of the field’s contents. For example, in the list of synonyms
for a gene in the Genome DataBase (GDB) there is the Unigene number, a number
from the NCBI system that relates a GenBank partition that serves as the reference
standard gene so that all researchers will use the same amino acid sequence as a
reference. In the Gene Ontology database, the IPI (International Protein Index)
number is listed in the synonym field. The IPI number references a set of database
records and amino acid sequences of the same protein in major protein databases. The
SWISS-PROT lists the Enzyme Commission number as a synonym although it is
more like a functional category.
Many of the genome knowledge bases have information on multiple species to allow for a
cross-species comparison of gene function. Whereas this is helpful for scientific research,
choosing the correct database entry is difficult since the gene symbols and gene names can be
very similar across species. Here, once again unlike most biomedical terms, the use of upper
and lower case often denotes meaning. For example, the gene symbol for the human fibrillin
1 gene is FBN1 while the gene symbol for the fibrillin 1 gene in the mouse is Fbn1. Further
ambiguity arises from the use of MFS1 as an alternate gene symbol for fibrillin 1 since
MFS1 is also used as an abbreviation for the disease Marfan Syndrome caused by a mutation
in the gene. Overall, it is fairly common for a disease name to be used as a synonym for a gene
name.
The lack of consistent use of terms leads to more difficulties with automated processing of the
data. An example comes from the Gene Ontology [15], the most widely used ontology in
molecular biology. It represents knowledge in three domains: molecular function, biological
process and cellular component. It uses terms as part of the ontology that are well known
through the biomedical literature, such as “protein tyrosine kinase”, but uses these terms in an
unusual sense. This entity can be found in many of the protein databases and is generally
understood to represent the biological molecule. But in the Gene Ontology, it is defined as the
enzyme reaction that it performs: “catalysis of the reaction: ATP + a protein tyrosine = ADP
+ protein tyro-sine phosphate”. Thus the term becomes shorthand for several entities that come
together to produce a chemical reaction, in addition to the connotation of being a specific
physical entity.
Discussion
Three major informatics issues of navigation and data complexity arose during the course of
this study:
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First, the official gene names are insufficient for navigation of these web resources. Navigation
is accomplished primarily by hotlinks. No single resource has all of the known symbols and
synonyms, although the HGNC provides the best list available. No universal identifying
number exists for genes and gene products, although there are attempts at such; e.g., the
International Protein Index (IPI) lists cross-reference numbers to identify entries representing
the same human protein across the SwissProt/Trembl, RefSeq, and Ensembl resources. The
parenthetical remarks, incomplete metadata, and lack of universal identifying numbers make
the gene names very difficult for computational navigation [13]. It is equally difficult to
navigate in the other direction: from specific genes to consumer-oriented disease descriptions
[14].
Second, navigational inconsistencies arise from difficulties in determining the number and
function of alternate forms of the gene or gene product and maintaining currency with the
information. The various resources do not agree on this information, a result of the different
updating cycles of each independent resource and the rapid pace of research.
Third, the issues involved with synonymy (multiple terms with the same meaning) and
polysemy (multiple meanings for the same term) cause much confusion. This is compounded
by the use of the synonym data fields to maintain cross-references to other systems. The use
of the same term for multiple meanings causes difficulties in determining whether the
appropriate information is retrieved and with frequent confusion of data categories, another
navigational hazard. All of these practices cause confusion in understanding, terminological
systems and navigation.
However, there are some knowledge representation tools and systems [15–20] being
developed, a testament to the recognized need for interoperability and traversal of
heterogeneous resources including such important considerations as links to the literature. The
Gene Ontology Consortium [21] has played a valuable role in the development of a controlled
vocabulary across species, although the genes themselves are not directly addressed by this
group. These tools can be augmented to improve the linkages between the health-related and
bioinformatics resources. An active research community holds promise that the situation will
improve.
Conclusion
There is a tremendous amount of data arising from the results of the Human Genome Project.
This study investigated the methods and resources to find associated data focused on the genes
and gene products related to a set of human disease genes. Specific informatics issues causing
hazards for computational navigation are (1) terminology inconsistencies especially with gene
names with parenthetical remarks and incomplete metadata; (2) navigational inconsistencies;
(3) inconsistent use of terms and methods of representing information.
Overall, such disparity exists between the focus of consumer health systems and bioinformatics
systems that uninterrupted manual or computational navigation from one type to another is
usually not successful. These are severe obstacles; tools and standards to facilitate this
navigation are sorely needed. The difficulties in finding the data are further compounded by
challenges of presenting it to a consumer audience. The answers to the public queries of “What
data is coming from the Human Genome Project that relates to my disease and my risks of
disease?” are increasingly available but not easily retrievable. Of course, even the best Internet
information system will not be able to replace diagnosis and guidance from qualified health
professionals.
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Navigation path from phenotype to genotype through the information resources used to answer
the questions of the study as they pertain to Marfan syndrome
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Table 2
The answers to the questions for the disease achondroplasia.
Seventeen separate information resources listed in Table 1 (MEDLINE, OMIM, LocusLink, GeneReviews,
GeneTests, Gene Ontology, HGMD, HGNC, GeneCards, PIR, ENZYME, DIP, Atlas of Cytogenetics in
Oncology and Hematology, Cancer.gov, RefSeq, ClinicalTrials.gov, UMLS) contained pieces of this data.
1 What genes cause the disease achondroplasia?
Achondroplasia is caused by a mutation in the FGFR3 gene. The official name for this gene is fibroblast growth factor receptor 3
(achondroplasia, thanatophoric dwarfism) and the official symbol is FGFR3.
2 On which chromosome are the genes located?
The FGFR3 gene is located at 4pl6.3. This is the short arm (p) of the fourth chromosome at band position 16.3.
3 What are the normal functions of the gene product?
The function of the FGFR3 gene is to code for a receptor protein that is embedded in the cell membrane. When a growth factor interacts with
the receptor protein, it triggers a chemical reaction that instructs a bone cell to get ready to grow or divide. The receptor protein regulates bone
growth by limiting the formation of bone from cartilage, particularly in the long bones.
4 What mutations have been found in these genes?
A mutation in a single base pair of the FGFR3 gene causes achondroplasia. 99% of the time this causes a substitution of the amino acid arginine
for glycine at position 380. 28 distinct mutations have been recorded in the literature for this gene, with the achondroplasia mutation being
the most frequently mutated site in the human genome. The other mutations cause other diseases (see question 8)
5 What are the functions of the mutated gene product?
Mutations in the gene cause the receptor to be overly active, leading to disturbances in bone growth. Different mutations lead to different rates
and kinds of bone growth disturbances.
6 What laboratories are performing DNA tests for the achondroplasia mutations?
There are 14 laboratories around the world that test for the achondroplasia mutations and other mutations in the FGFR3 gene.
7 Are there gene therapies or clinical trials for achondroplasia?
There are currently no clinical trials for achondroplasia, but there are clinical trials for the cancers (see question 8) caused by the FGFR3 gene
mutations.
8 Do the genes cause any other diseases in addition to achondroplasia?
Mutations in the gene cause seven distinct inherited syndromes: achondroplasia, thanatophoric dwarfism (type 1 and type 2), Crouzon
syndrome with acanthosis nigricans, hypochondroplasia, Muenke syndrome, and SADDAN dysplasia. Furthermore, if the FGFR3 gene is
mutated in a somatic cell during the adult life of a person, the person will likely develop one of four different cancers, depending in which
tissue the mutation arises: bladder cancer, cervical cancer, colorectal cancer, and multiple myeloma. The somatic mutations are often at the
same "hot spots" for mutation that cause skeletal dysplasias when they occur in the germ line. Mutations in other genes can also cause these
same cancers.
9 What names are used to refer to the genes, the gene products and the diseases in these resources?
The official name for this gene is fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism) and the official symbol is
FGFR3. In addition to the official names, sixteen alternate names and symbols are used for the gene and gene products (FGFR-3,
FGFR3_HUMAN, ACH, CEK2, JTK4, HSFGFR3EX, HBGFR, fibroblast growth factor receptor 3, FGFR-3 gene product, FGFR-3 protein,
fibroblast growth factor receptor 3 [precursor], tyrosyl protein kinase, protein-tyrosine kinase, human tyrosine kinase JTK4, tyrosine kinase
JTK4, and hydroxyarl-protein kinase). The gene has two different gene products (isoforms) called fibroblast growth factor receptor 3, isoform
1 precursor and fibroblast growth factor receptor 3, isoform 2 precursor, although the differences in their function is not understood. The
disease achondroplasia is also referred to as achondroplasia syndrome, achondroplasia dwarfism, chondrodystrophia, chondrodystrophia
fetalis, chondrodystrophia foetalis, chondrodystrophy syndrome, congential osteosclerosis, and osteosclerosis congenital.
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Table 3
Information resources that hold answers to the questions of the study.
The complete set of data to answer the questions only comes after traversing all resources. Note that while a
consumer audience can use OMIM to find information on almost all of these questions, it is generally considered
dense reading and not readily understandable.
1 What genes cause the disease?
a. GeneReviews, OMIM
2 On which chromosome are the genes located?
a. GeneCards, GeneReviews, LocusLink, MapViewer, OMIM
3 What are the normal functions of the gene product?
a. DIP, GeneCards, Gene Ontology, KEGG, OMIM, PER, PubMed, RefSeq, SwissProt
4 What mutations have been found in these genes?
a. HGMD, OMIM
5 What are the functions of the mutated gene product?
a. Atlas of Genetics and Cytogenetics in Oncology and Hematology, Cancer.gov, GeneReviews, OMIM, PubMed, RefSeq
6 What laboratories are performing DNA tests for the mutations?
a. GeneTests
7 Are there gene therapies or clinical trials for this disease?
a. ClinicalTrials.gov, GeneReviews, MEDLINEplus, OMIM, PubMed
8 Do the genes cause any other diseases in addition to the target disease?
a. GeneCards, GeneReviews, LocusLink, OMIM, PubMed
9 What names are used to refer to the genes and the diseases in these resources?
a. ENZYME, GDB, HGNC, IPI, LocusLink, OMIM, SwissProt, UMLS
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